Use novel properties of nanoparticles to engineer and progress to the clinic 2nd generation therapeutics to tackle major human diseases including cancer, malaria and asthma [ 2014 - ]

Research Grant

Researchers: Prof Magdalena Plebanski (Principal investigator)

Brief description Vaccines require adjuvants to be effective. Despite decades of research there is only one adjuvant approved for broad use in humans. Based on our prior findings I will engage new principles in nanotechnology, and deepen understanding of immune imprinting in various organs of the body including the lung, to develop 2nd generation broadly useful nanoadjuvants able to effectively treat cancer and malaria.

Funding Amount $601,420.00

Funding Scheme Research Fellowships

Notes Research Fellowship